Determining the value of drug development candidates and technology platforms

Kerstin M Bode-Greuel
Joachim M Greuel

DOI:https://doi.org/10.5912/jcb113

Abstract:

This paper explains a comprehensive and systematic approach to evaluate drug development projects and technology platforms, using an augmented version of net present value (NPV). The benefits of financial models for value-driven project and portfolio management, licensing negotiations and investors' decisions are discussed.

Keywords:valuation ,drug development ,technology platforms ,real options ,en ,